Blue Earth Diagnostics joins the British Institute of Radiology

OXFORD, UK – June 28, 2017 – Blue Earth Diagnostics has joined the British Institute of Radiology (BIR) as a corporate member.  BIR corporate members are encouraged to join the BIR community, to collaborate in developing educational events and to get involved with publishing activities.

Blue Earth Diagnostics is a UK-headquartered molecular imaging diagnostics company focused on the development of innovative PET imaging agents to inform clinical management and guide care for cancer patients.

Simon Thompson, Chief Executive of the BIR said, “We look forward to collaborating with Blue Earth Diagnostics, a dynamic company at the forefront of molecular imaging diagnostics and to learning more about their ground-breaking work.”

Dr Ted Broadbent, Global Brand Director at Blue Earth Diagnostics said “Collaborating with the BIR will give us a forum to share ideas and learn about the day-to-day challenges faced by the UK’s multidisciplinary medical imaging community.  We are delighted to be joining the BIR and look forward to becoming an active member of the society.”

About The British Institute of Radiology

The British Institute of Radiology is an international membership organisation for everyone working in imaging, radiation oncology and the underlying sciences.

Our aims are to:

  • support the work of our members and their colleagues to achieve professional excellence
  • provide continuing professional development for our multidisciplinary community
  • publish cutting-edge research for our authors and readers across the world
  • influence and connect with the wider professional sector.

Registered Charity No: 215869

About Blue Earth Diagnostics

Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company’s first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. The Company is funded by Syncona Limited, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.

CONTACTS

British Institute of Radiology

Carole Cross

Communications Manager

48-50 St John Street

London EC1M 4DG

T: 020 3668 2224

E: carole.cross@bir.org.uk

 

Blue Earth Diagnostics

Dr Val Jones

Val Jones PR Ltd

T: +44 7917 175192

E: v.jones@blueearthdx.com